PT0253 plus modified FOLFIRINOX shrank tumors in six of seven assessable patients with newly treated metastatic pancreatic cancer, according to preliminary Phase 1 results without a comparison group.
Experimental KRAS G12D Degrader Plus Chemotherapy Shrinks Tumors in 6 of 7 Assessed Pancreatic Cancer Patients
by | Nov 21, 2026 | Uncategorized | 0 comments

Recent Comments